India Remdesivir Saga: Exports Barred, Ramp Up Plans And Panic

Supply Situation Seen Easing

India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.

Banja Luka, Bosnia and Herzegovina, 18.3.2020. Concept of medical bottle with new possible cure for Coronavirus COVID 19. Remdesivir therapy for Korona virus medication potential drug
Remedesivir Supply Gap In India As COVID-19 Cases Spike • Source: Shutterstock

India has barred exports of remdesivir, Gilead Sciences, Inc.’s antiviral drug licensed to several domestic firms, amid a sharp spike in COVID-19 cases in the country.

With India reporting 152,879 new infections in 24 hours per government data on 11 April, there has been a huge...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia